Q-omics provides the consensus-scored RAB11FIP3 profile across patient tissues and cancer cell-line models. RAB11FIP3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAB11FIP3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, RAB11FIP3 RNA expression shows 20,176 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where RAB11FIP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB11FIP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB11FIP3 survival associations across molecular data types. RAB11FIP3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB11FIP3 RNA expression–survival associations across cancer types. High RAB11FIP3 expression shows unfavorable associations in UVM and LIHC, but favorable associations in PAAD, KIRC, BRCA and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAB11FIP3 RNA expression.
This table summarizes RAB11FIP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB11FIP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB11FIP3 shows lower tumor expression in BLCA, KICH and KIRP and higher tumor expression in COAD, LIHC and HNSC. The COAD box plot shows higher RAB11FIP3 RNA expression in tumor versus normal tissue (log2 FC = +1.122, t-test p < 0.001).
This table shows molecular features associated with RAB11FIP3 in patient tissues and cancer cell lines. In patient samples, RAB11FIP3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB11FIP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
